Duration of drug fixation at the edge of resection during targeted chemoembolization
https://doi.org/10.25789/YMJ.2021.75.11
Abstract
The duration of the presence of the drug in parenchyma of the organ, introduced into the edge of resection and fixed with a hemostatic suture was studied.
Transarterial injection of a contrast agent into the renal parenchyma and its subsequent fixation at the edge of resection with a hemostatic suture maintains a high concentration of the drug for a week after surgery. The presence of high concentrations of the targeted drug at the edge of the kidney resection in the early postoperative period will create an additional barrier of anti-contraction protection.
About the Authors
A. V. Maksimov
State Autonomous Institution of the Republic of Sakha (Yakutia) Republican Hospital №1 - National Center of Medicine
Russian Federation
Russian Federation
Maksimov Alexander Vasilievich – PhD, Head of the Urology Department
P. M. Ivanov
Medical Institute of the North-Eastern Federal University named after M.K. Ammosov
Russian Federation
Russian Federation
Ivanov Petr Mikhailovich – Doctor of Medical Sciences, Professor, Head of the Department of Oncology
F. G. Ivanova
State Budgetary Institution of the Republic of Sakha (Yakutia) Yakutsk Republican Oncological Dispensary
Russian Federation
Russian Federation
Ivanova Feodosia Gavrilyevna – PhD, Head of the Department of Anticancer Drug Therapy
P. A. Neustroev
Medical Institute of the North-Eastern Federal University named after M.K. Ammosov
Russian Federation
Russian Federation
Neustroev Petr Afanasyevich – PhD, Associate Professor of the Department of Hospital Surgery and Radiation Diagnostics
N. P. Kladkin
Republican Hospital №1 – National Medical Center
Russian Federation
Russian Federation
Kladkin Nyurgun Pavlovich – urologist of the urology department
References
1. Kobalava Zh.D., Shavarova E.K. Arterial hypertension during therapy of oncological diseases with angiogenesis inhibitors: serious impediment or controlled reaction? // Head and neck tumors. – 2017. – No. 7(2). – P. 70–80.
2. Maksimov A.V., Neustroev P.A. Method of balloon chemoembolization and resection of malignant tumors of parenchymal organs. RF patent for invention No. 2711549 // State Register of Inventions of the Russian Federation. 01/17/2020
3. Ivantsov A.O., Yanus G.A., Suspitsin E.N. et al. Molecular markers of sensitivity and resistance of colorectal cancer to anti-EGFR therapy // Siberian journal of oncology. – 2016. – No. 15(1). – P. 59–66.
4. Shevchenko A.N., Breus A.A., Neskubina I.V. et al. Evaluation of the prognostic significance of some biological factors in local and generalized clear cell renal cancer // South Russian Journal of Cancer. – 2020. – No. 1. –P. 6-22. https://doi.org/10.37748/2687-0533-2020-1-1-1.
5. Antiangiogenic therapy for cancer: an update / B. Al-Husein, M. Abdalla, M. Trepte [et al.] // Pharmacotherapy. – 2012. – №32(12). – P. 1095–111.
6. Elice F. Side effects of anti-angiogenic drugs / F. Elice, F. Rodeghiero // Thrombosis Research. – 2012. – №129. – P. 50–3.
7. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. / J. Summers, M.H. Cohen, P. Keegan [et al.] // Oncologist. – 2010. – №15. – P. 104–11.
8. Gampenrieder S.P. Antiangiogenic therapy in breast cancer. / S.P. Gampenrieder, T. Westphal, R. Greil // Memo. – 2017. – №10(4). – Р. 194–201.
9. Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. / Y. Haibe, M. Kreidieh, H. El Hajj [et al.] // Frontiers in Oncology. – 2020. – №10. – р. 221.
10. Rosen L.S. Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars / L.S. Rosen, I.A. Jacobs, R.L. Burkes // Target Oncol. – 2017. – №12. – Р. 599–610.
11. Zarrin B. Acquired tumor resistance to antiangiogenic therapy: Mechanisms at a glance / B. Zarrin, F. Zarifi, G. Vaseghi, S.H. Javanmard // J. Res. Med. Sci. – 2017. – №22. – Р. 117.
Review
For citations:
Maksimov A.V., Ivanov P.M., Ivanova F.G., Neustroev P.A., Kladkin N.P. Duration of drug fixation at the edge of resection during targeted chemoembolization. Yakut Medical Journal. 2021;(3):43-46. https://doi.org/10.25789/YMJ.2021.75.11
Views:
6
Email this article 